Yuviwel Kit
Product Images NDC 73362-201

Product Visual Gallery

This gallery contains 33 technical images submitted to the FDA as part of the official labeling for Yuviwel (NDC 73362-201). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascendis Pharma Endocrinology, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Yuviwel 01)

Chemical structure diagram of Navepegritide, the active ingredient in Yuviwel. The diagram shows the peptide sequence with labeled CNP moiety, TransCon linker, and mPEG moieties. Abbreviations include CNP for C-type natriuretic peptide and mPEG for methoxy polyethylene glycol.*

FDA Label Image

Image (Yuviwel 01a)

Instructional diagram featuring a QR code with accompanying text prompting to scan to watch an optional instructional video, including a play button icon below the text.*

FDA Label Image

Figure 1 (Yuviwel 02)

An instructional illustration depicting components of the Yuviwel kit by Ascendis Pharma Endocrinology, Inc. It shows a prefilled diluent syringe with labeled parts including plunger rod, diluent, and white cap; a preparation needle with safety shield and needle inside; and a Yuviwel vial containing medicine powder, shown both capped and uncapped.*

FDA Label Image

Figure 2 (Yuviwel 03)

An instructional diagram showing components of the Yuviwel injection kit by Ascendis Pharma Endocrinology, Inc. It illustrates an injection syringe with marked volume levels, a preparation needle with a safety shield, and an injection needle with both short and long needle caps highlighted.*

FDA Label Image

Figure 3 (Yuviwel 04)

An instructional illustration showing three medical components of the Yuviwel kit with orange caps or bases. Each part is labeled with 'Do not touch,' indicating areas to avoid contact: the vial top, the bottom of a syringe, and the end of a plunger syringe.*

FDA Label Image

Image (Yuviwel 04a)

Instructional image showing a QR code alongside text that reads 'Scan QR code to watch optional instruction video' with a play button icon on the right side.*

FDA Label Image

Figure A (Yuviwel 05)

An instructional illustration showing a hand holding a vial with the thumb and fingers, using the thumb to lift or remove the vial cap by applying an upward force indicated by an orange arrow. The background is light blue and the illustration is labeled with the letter 'A' in the upper left corner.*

FDA Label Image

Figure B (Yuviwel 06)

Illustration from the Yuviwel kit showing a hand holding a vial and another hand applying a wipe to the vial's cap, demonstrating preparation or cleaning of the vial before use.*

FDA Label Image

Figure C (Yuviwel 07)

Instructional illustration showing a hand removing the cap from a syringe needle while the other hand holds the syringe. This image is part of a step-by-step usage guide for the Yuviwel kit containing navepegritide, by Ascendis Pharma Endocrinology, Inc.*

FDA Label Image

Figure D (Yuviwel 08)

Instructional diagram depicting hands assembling two components of a medication delivery system. One hand holds a vial adaptor with a green tip, while the other hand holds a syringe, with an orange arrow indicating a twisting motion to connect the syringe to the vial adaptor. The image likely illustrates part of the preparation process for the Yuviwel Navepegritide kit by Ascendis Pharma Endocrinology, Inc.*

FDA Label Image

Figure E (Yuviwel 09)

Illustration showing a hand connecting a syringe to a vial or cartridge, likely as part of medication preparation or administration for the Yuviwel kit by Ascendis Pharma Endocrinology, Inc. The image includes directional arrows indicating the motion to attach or detach the syringe.*

FDA Label Image

Figure F (Yuviwel 10)

An illustration demonstrating the use of a prefilled syringe or injection device, with one hand holding a vial and the other hand pressing down on the syringe plunger to withdraw medication from the vial. An orange downward arrow indicates the syringe's movement into the vial.*

FDA Label Image

Figure G (Yuviwel 11)

Illustration showing a hand holding an injection device with a needle extending from the tip, likely demonstrating the preparation or administration step for a drug kit.*

FDA Label Image

Figure H (Yuviwel 12)

An instructional illustration showing a hand holding a small vial, with motion lines indicating shaking the vial. Next to it is a clock graphic showing 15 seconds, with an orange arrow between the clock and vial emphasizing shaking for 15 seconds.*

FDA Label Image

Figure I (Yuviwel 13)

Illustration showing a vial next to a clock graphic indicating a waiting time of 5 minutes. This instructional image likely relates to the preparation or use of Yuviwel (Navepegritide) kit by Ascendis Pharma Endocrinology, Inc.*

FDA Label Image

Figure J (Yuviwel 14)

Instructional illustration showing hands preparing a syringe, depicted by twisting an orange arrow indicating the removal or attachment of the syringe component. The image is related to the Yuviwel (Navepegritide) kit by Ascendis Pharma Endocrinology, Inc.*

FDA Label Image

Figure K (Yuviwel 15)

An instructional illustration showing a pair of hands handling a syringe. The diagram features an arrow pointing downward labeled 'Draw air,' indicating the step in preparation or use of the syringe within the Yuviwel kit by Ascendis Pharma Endocrinology, Inc.*

FDA Label Image

Figure L (Yuviwel 16)

An instructional illustration showing a hand holding a syringe and injecting air into a vial. The image includes a downward arrow labeled 'Inject air,' indicating the action to be performed. This diagram is part of usage directions for the Yuviwel Navepegritide kit from Ascendis Pharma Endocrinology, Inc.*

FDA Label Image

Figure M (Yuviwel 17)

An instructional diagram showing a hand holding a vial with a needle inserted into its rubber stopper, demonstrating the process of drawing liquid medication from the vial. The illustration includes a close-up circular inset highlighting the needle entering the vial's top.*

FDA Label Image

Figure N (Yuviwel 18)

Illustration showing proper technique for preparing a Yuviwel injection kit. It depicts a hand drawing liquid into a syringe from a vial, highlighting the importance of avoiding large air bubbles or air gaps. Small air bubbles in the syringe are shown as acceptable in the preparation process.*

FDA Label Image

Figure O (Yuviwel 19)

An instructional illustration showing a hand holding a syringe with a plunger and finger grip, along with a close-up magnified view highlighting a specific measurement mark on the syringe barrel. The orange arrow points to the indicated measurement, emphasizing correct alignment for dosage.*

FDA Label Image

Figure P (Yuviwel 20)

Illustration depicting a dosing pen device for the prescription drug Yuviwel (navepegritide) kit by Ascendis Pharma Endocrinology, Inc. The image shows the pen's dial and needle cover typically used for subcutaneous administration.*

FDA Label Image

Figure Q (Yuviwel 21)

Instructional illustration showing how to open a component by twisting in the middle of a yellow line. Two hands hold parts of a device being separated, with arrows indicating a twisting motion to access the inside of the nozzle.*

FDA Label Image

Figure R (Yuviwel 22)

An instructional illustration showing two hands preparing an injection pen device. The image demonstrates connecting or aligning parts of the pen, indicated by bidirectional arrows and a curved arrow for a twisting motion, likely to prime or assemble the device.*

FDA Label Image

Figure S (Yuviwel 23)

An instructional diagram showing two hands preparing a syringe device by twisting the barrel, likely part of the assembly or medication preparation process for Yuviwel (Navepegritide) Kit. The background is light green with a small dark blue box labeled 'S' in the top left corner.*

FDA Label Image

Figure T (Yuviwel 24)

An anatomical illustration highlighting four skin areas on the human body where the Yuviwel (Navepegritide) kit's application sites may be targeted. The areas shown are the right and left abdomen and the front upper thighs.*

FDA Label Image

Figure U (Yuviwel 25)

An instructional diagram depicting a human figure from the back with shaded areas on the upper arms and the buttocks, likely indicating recommended injection sites or application areas for the Yuviwel kit.*

FDA Label Image

Figure V (Yuviwel 26)

An instructional illustration showing a hand wiping a knee with a cloth or wipe, indicating a cleaning or preparation step. The image focuses on two knees with one knee being cleaned on the left side by the hand.*

FDA Label Image

Figure W (Yuviwel 27)

An instructional illustration showing hands holding a vial and a syringe, with orange arrows indicating pulling the vial and syringe apart. This likely demonstrates a step in medication preparation or injection technique for the Yuviwel kit by Ascendis Pharma Endocrinology, Inc.*

FDA Label Image

Figure X (Yuviwel 28)

Illustration depicting the administration technique for Yuviwel, showing a hand holding a syringe at a 45-degree angle to the outer thigh. The image demonstrates the proper injection angle into the skin.*

FDA Label Image

>principal Display Panel (1.3 mg Kit Carton)

Packaging label for Yuviwel (navepegritide) injection 1.3 mg/vial, a human prescription drug kit by Ascendis Pharma Endocrinology, Inc. The label indicates the product is for subcutaneous use only, single-dose vial, once-weekly injection, and includes details about kit contents and usage instructions. The label also displays the Ascendis Pharma logo and barcodes.*

FDA Label Image

Principal Display Panel (2.8 mg Kit Carton)

Packaging label for Yuviwel (navepegritide) 2.8 mg per vial for injection kit. The label indicates subcutaneous single-dose use, with a single weekly injection. The kit is distributed by Ascendis Pharma Endocrinology, Inc. and includes multiple components per carton, such as prefilled syringes and needles, instructions for use, and prescribing information. The label contains storage instructions and dosage information.*

FDA Label Image

Principal Display Panel (5.5 mg Kit Carton)

Packaging label for Yuviwel (navepegritide) injection, 5.5 mg/vial kit. The label indicates it is for subcutaneous use only, single-dose vial, and a once-weekly injection. The kit includes 4 kits and 1 patient information, with syringes, needles, sterile water, instructions, and prescribing information. The labeler is Ascendis Pharma Endocrinology, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.